An international study led by Dr. Fred Saad has resulted in the approval of a new treatment for metastatic castration-resistant prostate cancer. On December 16, the European Commission gave its positive endorsement to this combination treatment, a first for this stage of the disease.
More specifically, it concerns the use of Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer for whom chemotherapy is not clinically indicated.
To read AstraZeneca’s press release on this topic, click here.
Register for the Pancreatic Cancer Conference
22 April 2022
New this year, the Institute is launching registration for the conference, Pancreatic Cancer: Hopes for Treatment. Initiated by research members […]
Meriem Messaoudene receives $200,000 from the Seerave Foundation
5 October 2022
Meriem Messaoudene was chosen by the Seerave Foundation, a philanthropic organization, and will receive $200,000 to continue her work on castalagin […]